Compare Heron Therapeutics Inc (HRTX) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Matson Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Matson Inc trades at $229 (market cap $6.81B). The key difference: Matson Inc is far larger — about 100.1× Heron Therapeutics Inc's market cap, and Matson Inc pays a 0.67% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Matson Inc for 23 Days on average.
| HRTX | MATX | |
|---|---|---|
Market Cap | $68.01M | $6.81B |
Volume | 1,891,941 | 255,080 |
Sector | Health | Industrials |
52-Week High | $1.49 | $238.60 |
52-Week Low | $0.27 | $88.05 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $174.75M | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Matson (MATX) trades at $222.92, down 0.83% today, with neutral technical signals and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats, including Q2 2026 EPS of $4.27 versus $3.79 expected. Revenue growth continues with 2026 projections reaching $3.5 billion, supported by a 13.4% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment.
MATX presents a compelling investment case with solid profitability metrics and analyst support, though near-term technical resistance at $224 may limit upside. The company's raised full-year outlook and consistent dividend payments provide stability, while exposure to freight market volatility remains a key risk factor for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
